Compare GEVO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | SENS |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.8M | 301.2M |
| IPO Year | 2010 | 2014 |
| Metric | GEVO | SENS |
|---|---|---|
| Price | $1.54 | $9.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.58 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 3.1M | 712.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $711,000.00 | ★ $16,389,000.00 |
| Revenue This Year | $19.44 | $74.15 |
| Revenue Next Year | $5.59 | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $1.37 | $0.41 |
| 52 Week High | $2.97 | $9.19 |
| Indicator | GEVO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 81.58 |
| Support Level | $1.40 | $5.13 |
| Resistance Level | $1.57 | N/A |
| Average True Range (ATR) | 0.09 | 0.59 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 40.00 | 99.24 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.